Keigo Nishida

Ehime University

Papers

2

Total Citations

6

H-Index

2

About

Keigo Nishida is a pioneering urologic surgeon whose research focuses on advancing robotic-assisted surgery and refining treatment strategies for prostate cancer. His work critically examines the therapeutic value of extended pelvic lymph node dissection (ePLND) in intermediate- to high-risk prostate cancer patients undergoing robotic-assisted radical prostatectomy. In a highly cited 2025 study (4 citations), Nishida demonstrated that ePLND may not provide a significant biochemical recurrence benefit, challenging conventional surgical dogma and encouraging more selective, evidence-based lymph node management. Beyond clinical outcomes, Nishida is at the forefront of surgical innovation, evaluating the novel Japanese robotic platform HINOTORI™ against the established da Vinci® system. His comparative study in sacrocolpopexy (2 citations) highlights HINOTORI™’s potential to expand access and improve ergonomics in urologic robot-assisted surgery, including radical prostatectomy and partial nephrectomy. By combining rigorous outcomes research with technology assessment, Nishida is shaping the future of minimally invasive urology—prioritizing patient-centered care while driving adoption of next-generation surgical tools. His work offers critical insights for surgeons and trainees navigating the evolving landscape of robotic urology.

Research Focus

Key Achievements

2
H-Index
2
Papers
6
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Extended Lymph Node Dissection May Not Provide a Therapeutic Benefit in Patients with Intermediate-to High-Risk Prostate Cancer Treated with Robotic-Assisted Radical Prostatectomy
4 citations · 2025
📈 Most Prolific Year: 2025 (2 Papers)
🤝 Key Collaborators: 20
🏛 Institutions: Ehime University

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago